Sign in Subscribe
Vaccines

COVID-19 Vaccination in the United Kingdom: A Delicate Balance of Effectiveness and Protection

Strategic Insights

— 2 min read

COVID-19 vaccination has been deemed the most effective method to combat the pandemic, with over 221 million cases and 4.57 million deaths worldwide as of September 6, 2021. In the United Kingdom, three vaccines have been given emergency use authorization since December 8, 2020, namely the Pfizer/BioNTech BNT162b2 mRNA, Oxford/AstraZeneca ChAdOx1 nCoV-19 adenoviral AZD1222, and Moderna mRNA-1273 vaccines. These vaccines have shown varying levels of effectiveness, with two doses providing 65-90% protection against mild disease and 90-100% against severe disease.

Key Takeaways:

  • The Pfizer/BioNTech BNT162b2 and Oxford/AstraZeneca ChAdOx1 nCoV-19 vaccines have been found to be highly effective when administered with a two-dose schedule of three and four weeks, respectively.
  • A single dose of either vaccine provided 50-70% protection against infection and mild disease, as well as 75-80% protection against hospitalization and death.
  • The level of vaccine effectiveness increases to 65-90% against mild disease and 90-100% against severe disease after two doses.
  • The effectiveness of vaccines in at-risk groups, such as individuals with comorbidities, is not yet determined.
  • Research has shown that individuals with clinical comorbidities may have reduced seroconversion rates and antibody responses to vaccination.
  • A recent preprint study utilized electronic health records from a cohort of general practice patients to estimate vaccine effectiveness and antibody response in patients of different clinical risk groups.

Statistics:

  • Over 221 million COVID-19 cases and 4.57 million deaths have been reported worldwide as of September 6, 2021.
  • Three COVID-19 vaccines, Pfizer/BioNTech BNT162b2 mRNA, Oxford/AstraZeneca ChAdOx1 nCoV-19 adenoviral AZD1222, and Moderna mRNA-1273 vaccines, have been given emergency use authorization in the United Kingdom since December 8, 2020.
  • The Pfizer/BioNTech BNT162b2 vaccine has shown 90-100% effectiveness against severe disease after two doses.
  • The Oxford/AstraZeneca ChAdOx1 nCoV-19 vaccine has shown 65-90% effectiveness against mild disease after two doses.
  • Individuals with clinical comorbidities may have reduced seroconversion rates and antibody responses to vaccination.

Sources:

  • "The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus responsible for the coronavirus disease 2019 (COVID-19) has infected over 221 million and caused the deaths of over 4.57 million as of September 6, 2021."
  • "COVID-19 vaccination in the United Kingdom Since December 8, 2020, three different vaccines have been given emergency use authorization by the United Kingdoms Medicines and Healthcare Products Regulatory Agency (MHRA)."
  • "Prior to their approval, clinical trials found that the BNT162b2 and ChAdOx1-S vaccines were highly effective when a two-dose schedule with an interval of three and four weeks was used, respectively."
  • "A recent preprint study, [© 2021 Legal Monitor Worldwide. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)]"

Read more